
Lilly and J&J offer distinct paths for investors, with strong growth, expanding pipelines and key headwinds shaping their outlooks.
JNJ is down 1.15% today in the Healthcare sector. Volume is 0.

Lilly and J&J offer distinct paths for investors, with strong growth, expanding pipelines and key headwinds shaping their outlooks.

Three defensive blue chips entered 2026 promising safety, but their returns split into wildly different tiers, and the reason one name lapped the others exposes a fault line in ho…

One-Year Analytical Tool Delivers Near-Real-Time Pipeline Alerts on 481 Targets, 350 Deals, and 1,100+ Funding Rounds as Amgen, Roche, and J&J Lead a Field That Saw 278 New Drugs …

Report Features In-Depth Profiles of Abbott, Great Robotics, Intuitive Surgical, Johnson & Johnson, Medtronic, Panasonic, Renishaw, Siemens Healthineers, Smith+Nephew, Stryker, Zi…

Tyra Biosciences (TYRA) downgraded to Hold ahead of phase 2 SURF302 data; review FGFR3-targeting SNAP platform, cash runway, and key catalystsâread now.